S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
New iPhones Hot In A Bad Way, But Apple Stock Chart is Bullish
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
New iPhones Hot In A Bad Way, But Apple Stock Chart is Bullish
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
New iPhones Hot In A Bad Way, But Apple Stock Chart is Bullish
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
New iPhones Hot In A Bad Way, But Apple Stock Chart is Bullish
NYSE:CTLT

Catalent (CTLT) Stock Forecast, Price & News

$44.59
-0.94 (-2.06%)
(As of 10/2/2023 ET)
Compare
Today's Range
$43.95
$45.45
50-Day Range
$44.20
$50.20
52-Week Range
$31.45
$81.72
Volume
2.09 million shs
Average Volume
1.74 million shs
Market Capitalization
$8.04 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.17

Catalent MarketRank™ Forecast

Analyst Rating
Hold
2.31 Rating Score
Upside/​Downside
19.2% Upside
$53.17 Price Target
Short Interest
Healthy
5.71% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.09mentions of Catalent in the last 14 days
Based on 18 Articles This Week
Insider Trading
Acquiring Shares
$1.11 M Bought Last Quarter
Proj. Earnings Growth
118.57%
From $0.70 to $1.53 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

238th out of 975 stocks

Pharmaceutical Preparations Industry

89th out of 448 stocks


CTLT stock logo

About Catalent (NYSE:CTLT) Stock

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.

CTLT Price History

CTLT Stock News Headlines

Flee to Healthcare Stocks if Recession Rears its Head? (CTLT)
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.
Catalent (NYSE:CTLT) Price Target Cut to $50.00
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
FY2026 EPS Estimates for Catalent, Inc. Cut by Analyst (NYSE:CTLT)
Catalent Appoints David McErlane as Biologics Segment Leader
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Why Catalent Stock Zoomed 12% Higher This Week
15 Analysts Have This to Say About Catalent
Catalent (CTLT) Gets a Buy from RBC Capital
Catalent (CTLT) Q4 Earnings Miss Estimates
See More Headlines
Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

CTLT Company Calendar

Last Earnings
8/29/2023
Today
10/03/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
19,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$53.17
High Stock Price Forecast
$85.00
Low Stock Price Forecast
$43.00
Forecasted Upside/Downside
+19.2%
Consensus Rating
Hold
Rating Score (0-4)
2.31
Research Coverage
13 Analysts

Profitability

Net Income
$-232,000,000.00
Pretax Margin
-7.37%

Debt

Sales & Book Value

Annual Sales
$4.28 billion
Cash Flow
$1.42 per share
Book Value
$25.71 per share

Miscellaneous

Free Float
179,226,000
Market Cap
$8.04 billion
Optionable
Optionable
Beta
1.24
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. John J. Greisch M.B.A.Mr. John J. Greisch M.B.A. (Age 68)
    Exec. Chairman
    Comp: $125k
  • Mr. Alessandro  MaselliMr. Alessandro Maselli (Age 51)
    Pres, CEO & Director
    Comp: $1.53M
  • Dr. Aristippos Gennadios Ph.D. (Age 57)
    Group Pres of Pharma & Consumer Health Segment
    Comp: $1.13M
  • Mr. Matti M. Masanovich (Age 51)
    Sr. VP & CFO
  • Ms. Karen Murphy Santiago (Age 52)
    VP & Chief Accounting Office
  • Mr. Charles  LickfoldMr. Charles Lickfold (Age 49)
    Sr. VP & Chief Information Officer
  • Mr. Paul Surdez
    VP of Investor Relations
  • Mr. Joseph A. Ferraro J.D. (Age 44)
    Sr. VP, Gen. Counsel, Chief Compliance Officer & Sec.
  • Mr. Michael J. GrippoMr. Michael J. Grippo (Age 54)
    Sr. VP of Strategy & Corp. Devel.
  • Ms. Lisa Evoli (Age 53)
    Sr. VP & Chief HR Officer













CTLT Stock - Frequently Asked Questions

Should I buy or sell Catalent stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 sell rating, 7 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CTLT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTLT, but not buy additional shares or sell existing shares.
View CTLT analyst ratings
or view top-rated stocks.

What is Catalent's stock price forecast for 2023?

13 Wall Street analysts have issued 12 month target prices for Catalent's stock. Their CTLT share price forecasts range from $43.00 to $85.00. On average, they anticipate the company's share price to reach $53.17 in the next year. This suggests a possible upside of 19.2% from the stock's current price.
View analysts price targets for CTLT
or view top-rated stocks among Wall Street analysts.

How have CTLT shares performed in 2023?

Catalent's stock was trading at $45.01 at the beginning of the year. Since then, CTLT shares have decreased by 0.9% and is now trading at $44.59.
View the best growth stocks for 2023 here
.

Are investors shorting Catalent?

Catalent saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 10,300,000 shares, a decrease of 6.3% from the August 31st total of 10,990,000 shares. Based on an average daily volume of 2,440,000 shares, the short-interest ratio is presently 4.2 days.
View Catalent's Short Interest
.

When is Catalent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our CTLT earnings forecast
.

How were Catalent's earnings last quarter?

Catalent, Inc. (NYSE:CTLT) released its quarterly earnings data on Tuesday, August, 29th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by $0.02. The business earned $1.09 billion during the quarter, compared to analyst estimates of $1.05 billion. Catalent had a negative net margin of 5.43% and a positive trailing twelve-month return on equity of 3.24%. The firm's revenue for the quarter was down 15.6% on a year-over-year basis. During the same period last year, the business posted $1.12 EPS.
Read the conference call transcript
.

What guidance has Catalent issued on next quarter's earnings?

Catalent issued an update on its FY 2024 earnings guidance on Tuesday, August, 29th. The company provided earnings per share guidance of $0.62-$0.96 for the period, compared to the consensus earnings per share estimate of $1.14. The company issued revenue guidance of $4.30 billion-$4.50 billion, compared to the consensus revenue estimate of $4.19 billion.

What is John R. Chiminski's approval rating as Catalent's CEO?

391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

How do I buy shares of Catalent?

Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $44.59.

How much money does Catalent make?

Catalent (NYSE:CTLT) has a market capitalization of $8.04 billion and generates $4.28 billion in revenue each year. The company earns $-232,000,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis.

How many employees does Catalent have?

The company employs 19,000 workers across the globe.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The official website for the company is www.catalent.com. The company can be reached via phone at (732) 537-6200, via email at investors@catalent.com, or via fax at 732-537-6480.

This page (NYSE:CTLT) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -